Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: Implications for spinocerebellar ataxia type 1 therapy

Molecular Therapy

Volumn 22, Issue 3, 2014, Pages 588-595

  Keiser, Megan S ^a   Boudreau, Ryan L ^b   Davidson, Beverly L ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 1; PARVOVIRUS VECTOR; POLYGLUTAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN STEM; CEREBELLUM CORTEX; CEREBELLUM NUCLEUS; CONTROLLED STUDY; ENZYME REPRESSION; FEMALE; HISTOLOGY; KNOCKIN MOUSE; MALE; MOUSE; MOUSE MODEL; NERVE DEGENERATION; NONHUMAN; PROTEIN EXPRESSION; PURKINJE CELL; RNA INTERFERENCE; RNA SEQUENCE; ROTAROD TEST; SPINOCEREBELLAR ATAXIA TYPE 1; SPINOCEREBELLAR DEGENERATION;

ADENO-ASSOCIATED VIRUS; MUS;

ANIMALS; CEREBELLAR CORTEX; CEREBELLAR NUCLEI; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; FEMALE; GENE KNOCK-IN TECHNIQUES; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; RNA INTERFERENCE; SPINOCEREBELLAR ATAXIAS;

EID: 84895468010     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.279     Document Type: Article

References (49)

1. Orr, HT (2012). Polyglutamine neurodegeneration: expanded glutamines enhance native functions. Curr Opin Genet Dev 22: 251-255.
2. Banfi, S, Servadio, A, Chung, MY, Kwiatkowski, TJ Jr, McCall, AE, Duvick, LA et al. (1994). Identification and characterization of the gene causing type 1 spinocerebellar ataxia. Nat Genet 7: 513-520.
3. Zoghbi, HY and Orr, HT (1995). Spinocerebellar ataxia type 1. Semin Cell Biol 6: 29-35.
4. Orr, HT, Chung, MY, Banfi, S, Kwiatkowski, TJ Jr, Servadio, A, Beaudet, AL et al. (1993). Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet 4: 221-226.
5. Donato, SD, Mariotti, C and Taroni, F (2012). Spinocerebellar ataxia type 1. Handb Clin Neurol 103: 399-421.
6. Zu, T, Duvick, LA, Kaytor, MD, Berlinger, MS, Zoghbi, HY, Clark, HB et al. (2004). Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J Neurosci 24: 8853-8861.
7. Oz, G, Nelson, CD, Koski, DM, Henry, PG, Marjanska, M, Deelchand, DK et al. (2010). Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J Neurosci 30: 3831-3838.
8. Boudreau, RL, McBride, JL, Martins, I, Shen, S, Xing, Y, Carter, BJ et al. (2009). Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 17: 1053-1063.
9. McBride, JL, Pitzer, MR, Boudreau, RL, Dufour, B, Hobbs, T, Ojeda, SR et al. (2011). Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol Ther 19: 2152-2162.
10. Xia, H, Mao, Q, Eliason, SL, Harper, SQ, Martins, IH, Orr, HT et al. (2004). RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 10: 816-820.
11. Xia, H, Mao, Q, Paulson, HL and Davidson, BL (2002). siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 20: 1006-1010.
12. Kole, R, Krainer, AR and Altman, S (2012). RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11: 125-140.
13. Serra, HG, Duvick, L, Zu, T, Carlson, K, Stevens, S, Jorgensen, N et al. (2006). RORalpha-mediated Purkinje cell development determines disease severity in adult SCA1 mice. Cell 127: 697-708.
14. Tsuda, H, Jafar-Nejad, H, Patel, AJ, Sun, Y, Chen, HK, Rose, MF et al. (2005). The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/ Senseless proteins. Cell 122: 633-644.
15. Watase, K, Gatchel, JR, Sun, Y, Emamian, E, Atkinson, R, Richman, R et al. (2007). Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med 4: e182.
16. Rodriguez-Lebron, E, Liu, G, Keiser, M, Behlke, MA and Davidson, BL (2013). Altered Purkinje cell miRNA expression and SCA1 pathogenesis. Neurobiol Dis 54: 456-463.
17. Davidson, BL and McCray, PB Jr (2011). Current prospects for RNA interference-based therapies. Nat Rev Genet 12: 329-340.
18. Boudreau, RL and Davidson, BL (2010). RNAi therapeutics for CNS disorders. Brain Res 1338: 112-121.
19. Boudreau, RL, Rodríguez-Lebrón, E and Davidson, BL (2011). RNAi medicine for the brain: progresses and challenges. Hum Mol Genet 20(R1): R21-R27.
20. Keiser, MS, Geoghegan, JC, Boudreau, RL, Lennox, KA and Davidson, BL (2013). RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1. Neurobiol Dis 56: 6-13.
21. Watase, K, Weeber, EJ, Xu, B, Antalffy, B, Yuva-Paylor, L, Hashimoto, K et al. (2002). A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 34: 905-919.
22. Bowman, AB, Lam, YC, Jafar-Nejad, P, Chen, HK, Richman, R, Samaco, RC et al. (2007). Duplication of Atxn1l suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes. Nat Genet 39: 373-379.
23. Fryer, JD, Yu, P, Kang, H, Mandel-Brehm, C, Carter, AN, Crespo-Barreto, J et al. (2011). Exercise and genetic rescue of SCA1 via the transcriptional repressor Capicua. Science 334: 690-693.
24. Boudreau, RL, Spengler, RM and Davidson, BL (2011). Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. Mol Ther 19: 2169-2177.
25. Boudreau, RL, Spengler, RM, Hylock, RH, Kusenda, BJ, Davis, HA, Eichmann, DA et al. (2013). siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse. Nucleic Acids Res 41: e9.
26. Davidson, BL and Boudreau, RL (2007). RNA interference: a tool for querying nervous system function and an emerging therapy. Neuron 53: 781-788.
27. Chen, C, Ridzon, DA, Broomer, AJ, Zhou, Z, Lee, DH, Nguyen, JT et al. (2005). Realtime quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179.
28. Tang, F, Hajkova, P, Barton, SC, Lao, K and Surani, MA (2006). MicroRNA expression profiling of single whole embryonic stem cells. Nucleic Acids Res 34: e9.
29. McBride, JL, Boudreau, RL, Harper, SQ, Staber, PD, Monteys, AM, Martins, I et al. (2008). Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 105: 5868-5873.
30. Knöpfel, T and Grandes, P (2002). Metabotropic glutamate receptors in the cerebellum with a focus on their function in Purkinje cells. Cerebellum 1: 19-26.
31. Serra, HG, Byam, CE, Lande, JD, Tousey, SK, Zoghbi, HY and Orr, HT (2004). Gene profiling links SCA1 pathophysiology to glutamate signaling in Purkinje cells of transgenic mice. Hum Mol Genet 13: 2535-2543.
32. Jafar-Nejad, P, Ward, CS, Richman, R, Orr, HT and Zoghbi, HY (2011). Regional rescue of spinocerebellar ataxia type 1 phenotypes by 14-3-3epsilon haploinsufficiency in mice underscores complex pathogenicity in neurodegeneration. Proc Natl Acad Sci USA 108: 2142-2147.
33. Vig, PJ, Hearst, S, Shao, Q, Lopez, ME, Murphy, HA 2nd and Safaya, E (2011). Glial S100B protein modulates mutant ataxin-1 aggregation and toxicity: TRTK12 peptide, a potential candidate for SCA1 therapy. Cerebellum 10: 254-266.
34. Lam, YC, Bowman, AB, Jafar-Nejad, P, Lim, J, Richman, R, Fryer, JD et al. (2006). ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell 127: 1335-1347.
35. Crespo-Barreto, J, Fryer, JD, Shaw, CA, Orr, HT and Zoghbi, HY (2010). Partial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesis. PLoS Genet 6: e1001021.
36. Takács, J, Gombos, G, Görcs, T, Becker, T, de Barry, J and Hámori, J (1997). Distribution of metabotropic glutamate receptor type 1a in Purkinje cell dendritic spines is independent of the presence of presynaptic parallel fibers. J Neurosci Res 50: 433-442.
37. Aiba, A, Kano, M, Chen, C, Stanton, ME, Fox, GD, Herrup, K et al. (1994). Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice. Cell 79: 377-388.
38. Ichise, T, Kano, M, Hashimoto, K, Yanagihara, D, Nakao, K, Shigemoto, R et al. (2000). mGluR1 in cerebellar Purkinje cells essential for long-term depression, synapse elimination, and motor coordination. Science 288: 1832-1835.
39. Pekhletski, R, Gerlai, R, Overstreet, LS, Huang, XP, Agopyan, N, Slater, NT et al. (1996). Impaired cerebellar synaptic plasticity and motor performance in mice lacking the mGluR4 subtype of metabotropic glutamate receptor. J Neurosci 16: 6364-6373.
40. Cvetanovic, M, Patel, JM, Marti, HH, Kini, AR and Opal, P (2011). Vascular endothelial growth factor ameliorates the ataxic phenotype in a mouse model of spinocerebellar ataxia type 1. Nat Med 17: 1445-1447.
41. Lambrechts, D and Carmeliet, P (2006). VEGF at the neurovascular interface: therapeutic implications for motor neuron disease. Biochim Biophys Acta 1762: 1109-1121.
42. Oosthuyse, B, Moons, L, Storkebaum, E, Beck, H, Nuyens, D, Brusselmans, K et al. (2001). Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28: 131-138.
43. Sopher, BL, Thomas, PS Jr, LaFevre-Bernt, MA, Holm, IE, Wilke, SA, Ware, CB et al. (2004). Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. Neuron 41: 687-699.
44. Glickstein, M and Doron, K (2008). Cerebellum: connections and functions. Cerebellum 7: 589-594.
45. Thach, WT, Goodkin, HP and Keating, JG (1992). The cerebellum and the adaptive coordination of movement. Annu Rev Neurosci 15: 403-442.
46. Boudreau, RL, Monteys, AM and Davidson, BL (2008). Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA 14: 1834-1844.
47. Boudreau, RL, Martins, I and Davidson, BL (2009). Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther 17: 169-175.
48. Urabe, M, Ding, C and Kotin, RM (2002). Insect cells as a factory to produce adenoassociated virus type 2 vectors. Hum Gene Ther 13: 1935-1943.
49. McLoughlin, HS, Fineberg, SK, Ghosh, LL, Tecedor, L and Davidson, BL (2012). Dicer is required for proliferation, viability, migration and differentiation in corticoneurogenesis. Neuroscience 223: 285-295.